【24h】

Asthma

机译:哮喘

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Asthma-one of the most common chronic, non-communicable diseases in children and adults-is characterised by variable respiratory symptoms and variable airflow limitation. Asthma is a consequence of complex gene-environment interactions, with heterogeneity in clinical presentation and the type and intensity of airway inflammation and remodelling. The goal of asthma treatment is to achieve good asthma control-ie, to minimise symptom burden and risk of exacerbations. Anti-inflammatory and bronchodilator treatments are the mainstay of asthma therapy and are used in a stepwise approach. Pharmacological treatment is based on a cycle of assessment and re-evaluation of symptom control, risk factors, comorbidities, side-effects, and patient satisfaction by means of shared decisions. Asthma is classed as severe when requiring high-intensity treatment to keep it under control, or if it remains uncontrolled despite treatment. New biological therapies for treatment of severe asthma, together with developments in biomarkers, present opportunities for phenotype-specific interventions and realisation of more personalised treatment. In this Seminar, we provide a clinically focused overview of asthma, including epidemiology, pathophysiology, clinical diagnosis, asthma phenotypes, severe asthma, acute exacerbations, and clinical management of disease in adults and children older than 5 years. Emerging therapies, controversies, and uncertainties in asthma management are also discussed.
机译:哮喘 - 儿童和成人最常见的慢性,非传染性疾病之一 - 以可变呼吸症状和可变气流限制为特征。哮喘是复杂的基因环境相互作用的结果,临床介绍中的异质性以及气道炎症和重塑的类型和强度。哮喘治疗的目标是实现良好的哮喘控制 - 即,以最大限度地减少症状负担和加剧风险。抗炎和支气管扩张剂治疗是哮喘治疗的主要支柱,并以逐步的方法使用。药理治疗基于评估,并通过共同决策进行评估,危险因素,机理,副作用和患者满意度的循环。当需要高强度处理时,哮喘被归类为严重,以便在控制下保持它,或者尽管治疗仍然不受控制。新的生物疗法治疗严重哮喘,以及生物标志物的发展,目前表型特异性干预的机会和更加个性化的治疗。在本次研讨会中,我们提供临床上专注的哮喘概述,包括流行病学,病理生理学,临床诊断,哮喘表型,严重的哮喘,急剧加剧以及成人和5年龄的儿童疾病的临床管理。还讨论了哮喘管理中的新兴疗法,争议和不确定性。

著录项

  • 来源
    《The Lancet》 |2018年第10122期|共18页
  • 作者单位

    Univ Ferrara Dept Med Sci Res Ctr Asthma &

    COPD I-44121 Ferrara Italy;

    Univ Leicester Dept Infect Immun &

    Inflammat Inst Lung Hlth Leicester Natl Inst Hlth Res Biomed;

    Univ Southern Denmark Kolding Hosp Dept Paediat Kolding Denmark;

    Univ Sydney Clin Management Grp Woolcock Inst Med Res Sydney NSW Australia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医药、卫生;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号